Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Executive Summary
Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.
You may also be interested in...
Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers
Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside Medicare's reimbursement bundle for end-stage renal disease.
Harper, Hooper Exit As Amgen Revenues Rise
Amgen revealed better-than-expected second quarter earnings July 26 and said its R&D and commercial heads Sean Harper and Anthony Hooper are retiring. Harper, who's getting involved with start-ups, is being replaced from within by David Reese; Bristol's Murdo Gordon will take over for Hooper.
Harper, Hooper Exit As Amgen Revenues Rise
Amgen revealed better-than-expected second quarter earnings July 26 and said its R&D and commercial heads Sean Harper and Anthony Hooper are retiring. Harper, who's getting involved with start-ups, is being replaced from within by David Reese; Bristol's Murdo Gordon will take over for Hooper.